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Objectives: Network meta-analysis (NMA) is increasingly used to inform reim-
bursement decisions and comparative effectiveness. Nevertheless, there is limited 
understanding of the assessment of statistical power, particularly when there is a 
small number of studies available. We propose an empirical calculation for statistical 
power using a simulation approach. MethOds: Simulation data were generated in 
minimum of 3 to maximum of 15 studies per network, using varying effect sizes and 
standard errors under the exchangeability assumption; where trial-specific treat-
ment effects (δ ij) came from a common distribution with mean (dij ) and variance 
(σ 2). The common distribution is usually chosen to be a normal distribution, so that 
δ ij˜N(dij, σ 2) where i,j are different treatments. Upon generation of simulation data, 
Bayesian methods were applied to each simulation set. This was repeated at least 
1000 times, which enabled the estimation of the statistical power. We compared 
the results of simulations to the gold standard, defined by available data from each 
study, and Thorlund’s method. Results: The proposed method was successful in 
estimating the statistical power and the minimum number of studies needed, using 
simulation data from an NMA, compared to the gold standard. The estimations 
for statistical power/number of studies needed by different effect sizes, standard 
errors, and noise levels were compared with Thorlund’s method showing more 
accuracy to estimate statistical power for NMA. Our method offers flexibility and 
can be implemented with Normal, Binomial, and Poisson distributions. Further, it 
can also handle multiple treatments, fixed/random effects models, and multi-arms 
studies. cOnclusiOns: While it is difficult to derive a mathematical formula for 
estimating statistical power and the number of studies needed in NMA because 
of increased complexity caused by multiple treatment comparisons, an empirical 
method using simulations allows for estimation of these quantities. The proposed 
method will be useful for researchers designing NMA to inform decision makers.
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Objectives: to measure the DM social cost based in earnings losses of Brazilian 
workers due to disease in 2008 using data from National Survey of Households 
(PNAD/IBGE). Diabetes Mellitus (DM) is characterized by the high level of blood glu-
cose. Ministry of Health data estimated that Brazil had about 10 million DM cases in 
2010, being the fourth main cause of death. WHO estimated the prevalence of DM in 
Brazil is 10.2%, about 20 million people. MethOds: a Binary Probit model to meas-
ure the participation in work force and a two-stage Heckman model to measure 
worked hours and productivity. Each model is estimated separately for both gender 
individuals, with and without disease, according three distinct definitions for DM: 
Restrict, Broad and Comorbidities. To capture the counterfactual effect, the model 
was calculated for ill and healthy individuals. The difference of both values exhib-
ited the losses, which were aggregate to the whole population and the total cost 
was estimated. Results: According each criterion, respectively, DM reduced the 
participation in the labor market in 0,97%; 4,60% and 7,06% for men and 0,14%; 4,79% 
and 6,44% for women, while reduced, respectively 1,51%; 6,40% and 9,15% in produc-
tivity and 6,44%; 15,23% and 17,58% in worked hours just for women. There was no 
impact of DM on productivity and in worked hours for men. The DM total cost was 
R$ 8,064 billion, or US$ 3,451 billion converted by current exchange rate. The losses 
reached 0,73% of total earnings and 0,27% of Brazilian GDP in 2008. cOnclusiOns: 
DM generates significant losses in income of Brazilian workers, especially in relation 
to their participation in the labor market, since affects both of gender. The results 
indicate that public policies should be directed to disease diagnosis and prevention, 
since the development of comorbidities amplifies the effect of losses.
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Objectives: Cluster analysis (CA) is a widely used statistical technique that helps 
reveal classifications of entities with similar characteristics in large data sets. 
However, little is known about whether it can be applied to healthcare claims data 
with highly skewed cost information. This study applied different clustering meth-
ods to changes in all-cause cost data from a group of patients with end stage renal 
disease (ESRD) who initiated hemodialysis (HD). MethOds: A retrospective, cross-
sectional, observational study was conducted using the MarketScan Commercial 
Claims database. Patients aged ≥18 years with ≥2 ESRD diagnoses who initiated HD 
between 2008 and 2010 were included. The K-means CA method and hierarchical 
CA with various linkage methods were applied to all-cause costs within baseline 
(12-month pre-HD) and follow-up periods (12-month post-HD) to identify clusters. 
Demographic, clinical, and cost information were extracted from both periods, 
and then examined by cluster. Results: A total of 18,380 patients were identified. 
Meaningful all-cause cost clusters were generated using K-means and hierarchical 
CA with either flexible beta or Ward’s methods. Based on cluster sample sizes and 
change of cost patterns, the K-means CA method and 4 clusters were selected: 
those with average costs in both periods (n=16,624); high costs followed by very 
high costs (n=113); high and increasing costs (n=1,554); or very high costs reduced 
to high cost (n=89). Relatively stable costs after starting HD were associated with 
more stable scores on comorbidity index scores from the pre- and post-HD periods, 
while increasing costs were associated with more sharply increasing comorbidity 
by Signorovitch (WS) vs. Entropy Balancing (EB). WS is based on propensity 
score weights (odds of being in AGR trial) while EB relies on a maximum entropy 
reweighting scheme. Results: Simulation show the optimal weighting method 
is to match on covariates against the AGR treatment and control arms separately. 
In addition, rebalancing on prognostic variables between the IPD arms using EB 
is beneficial when they are not reported in AGR. For example, with true treat-
ment mean difference between AGR and IPD (IC) of one, six predictive variables 
in AGR and IPD and three prognostic variables in IPD, the Bucher method gives a 
biased estimate 0.31(Average Bootstrap 95% Confidence interval: -0.45, 1.08). WS 
balancing gives 0.99(0.23 –1.73), balancing on each arm separately gives 0.99(0.30-
1.68) while rebalancing using EB gives 0.99(0.47-1.52). Also, simulations demon-
strate that including placebo response into the weighting in addition to baseline 
covariates can produce biased results and is not recommended. cOnclusiOns: 
MAIC can be improved if weighting is performed on each arm separately 
together with rebalancing of the IPD on the prognostic variables not reported 
in AGR.
PRM125
PsychotRoPic PhaRMacothERaPy associatEd with Qt PRolonGation 
aMonG vEtERans with PosttRauMatic stREss disoRdER
Stock E.M.1, Zeber J.E.1, McNeal C.J.2, Banchs J.E.2, Copeland L.A.1
1Center for Applied Health Research - Central Texas Veterans Health Care System jointly with 
Baylor Scott & White Health, Temple, TX, USA, 2Baylor Scott & White Health, Temple, TX, USA
Objectives: In 2012, the FDA issued Drug Safety Communications on several 
drugs associated with QT prolongation and fatal ventricular arrhythmias. Among 
these was citalopram, a selective serotonin reuptake inhibitor (SSRI) commonly 
used to treat posttraumatic stress disorder (PTSD). As minimal research has 
assessed drug-related QT prolongation in patients with severe mental illnesses, 
this study explores psychotropic drugs associated with QT prolongation among 
Veterans diagnosed with PTSD. MethOds: Patients with PTSD in the Veterans 
Health Administration in 2006-2009 were reviewed, identifying 176 Veterans diag-
nosed with QT prolongation. Cases were matched 1:4 on age, gender, visit date and 
setting, and physical comorbidity. Classification trees assessed QT prolongation 
risk among prescribed medications for the combined sample (N= 880). Finally, 
five-year survival by prolonged QT status was analyzed. Results: Receipt of any 
drug with known risk of QT prolongation varied by group (23% QT vs. 15% con-
trol, p< 0.01). Psychotropic medications conferring significant risks included the 
antipsychotic ziprasidone (3% vs. 1%, p= 0.02) and the anxiolytic buspirone (6% 
vs. 2%, p= 0.01) but not the SSRIs citalopram and fluoxetine. Classification trees 
found sotalol and the tricyclic antidepressant amitriptyline carried greater risk 
among cardiac patients, and methadone, especially if prescribed with quetiapine, 
among non-cardiac patients. Per preliminary adjusted survival model, patients 
with QT prolongation were at increased risk for mortality (HR= 1.60; 95% CI: 1.04-
2.44). cOnclusiOns: Decision models are particularly advantageous when 
exploring nonlinear relationships or non-additive interactions. These findings 
may potentially impact clinical decision-making concerning treatment for PTSD. 
For patients at higher risk of QT prolongation, antidepressants other than ami-
triptyline should be considered. Medications for comorbid conditions should also 
be closely monitored for heightened risk of QT prolongation. This study further 
highlights the importance of routine use of electrocardiograms for QT monitoring 
among patients with PTSD taking these agents.
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Objectives: Methods of analyzing real world evidence (RWE) have tradition-
ally focused on population-based outcome assessments, whereas the applica-
tion of RWE to address healthcare decision making for the individual patient 
is less well established. The primary objective of this study was to systemati-
cally review published methods using real world data sources to inform patient-
level and patient-provider decision making. MethOds: A systematic literature 
review was conducted in MEDLINE and PsychInfo from 1/1/2000 to 9/18/2014. The 
search strategy included methodology, design and limited publications to can-
cer, diabetes, cardiovascular, Alzheimer’s disease, and rheumatologic conditions. 
A review of reference lists of identified articles enhanced the search strategy. 
Eligible studies were quantitative research that described statistical method-
ologies applicable to patient-provider decision making. Non-English and non-
human studies were excluded. Articles were also excluded if they were qualitative 
research studies, reviews, policy/guidelines statements, or studies solely inves-
tigating a provider’s perspective. Following dual eligibility review, details of the 
study and research methodology were extracted and summarized. Results: The 
search strategy identified 1088 publications. A preliminary review of 594 articles 
found 46 that were eligible. The methodologies used included prediction models 
based on logistic, multiple regression and Cox-regression models, multivariate 
risk analyses, discrete choice experiments, net reclassification, and classifica-
tion trees. The review is currently ongoing and additional eligible articles will 
be identified. Details of the application of these methods to patient-provider 
decision making will be presented at the meeting. cOnclusiOns: There is a 
need to incorporate methods in research studies to support evidence-based 
patient-level decision making. This systematic literature review has sought to 
identify methods and exemplars that will enable researchers to produce work to 
inform patient-provider decision making. This review will make recommenda-
tions regarding appropriate methods for scientists and investigators conducting 
patient-centered research. Future research should consider these approaches 
to incorporate methods that will support evidence-based patient decision 
making.
